AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 103 filers reported holding AVROBIO INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $25,000 | -67.9% | 18,810 | -6.6% | 0.00% | – |
| Q4 2021 | $78,000 | -32.8% | 20,134 | -2.9% | 0.00% | -100.0% |
| Q3 2021 | $116,000 | -35.9% | 20,737 | +2.0% | 0.00% | 0.0% |
| Q2 2021 | $181,000 | -31.2% | 20,326 | -1.9% | 0.00% | 0.0% |
| Q1 2021 | $263,000 | +4.0% | 20,710 | +14.0% | 0.00% | 0.0% |
| Q4 2020 | $253,000 | +4.1% | 18,160 | -2.8% | 0.00% | 0.0% |
| Q3 2020 | $243,000 | -26.4% | 18,682 | -1.1% | 0.00% | -50.0% |
| Q2 2020 | $330,000 | +52.8% | 18,892 | +36.1% | 0.00% | +100.0% |
| Q1 2020 | $216,000 | -16.9% | 13,877 | +7.5% | 0.00% | 0.0% |
| Q4 2019 | $260,000 | +41.3% | 12,904 | -0.8% | 0.00% | 0.0% |
| Q3 2019 | $184,000 | +13.6% | 13,013 | +30.5% | 0.00% | 0.0% |
| Q2 2019 | $162,000 | -9.5% | 9,972 | +22.9% | 0.00% | 0.0% |
| Q1 2019 | $179,000 | +167.2% | 8,111 | +102.2% | 0.00% | – |
| Q4 2018 | $67,000 | -68.1% | 4,011 | -0.7% | 0.00% | -100.0% |
| Q3 2018 | $210,000 | – | 4,041 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |